Drawing for BIOTEST

USPTO serial 76720853

BIOTEST

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
Examiner
HUSSAIN, TASNEEM
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with BIOTEST?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*

Plus Government fees of $300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John W. McGlynn

John W. McGlynn Buchanan Ingersoll & Rooney, P.C.2200 Renaissance BoulevardSuite 350King of Prussia, PA 19406

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations for use in industry and science, namely, proteins and protein preparations made from human blood, blood plasma or blood serum, in particular human albumin, coagulation factors and immunoglobulins; recombinant proteins for industrial and scientific use; plasma fractions in the nature of biological preparations for industrial and scientific use; excipients for the stabilization of medicines, in particular human albumin for industrial and scientific purposesACTIVE
005Pharmaceutical preparations for treating infectious diseases and diseases of the immune system, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; pharmaceutical preparations for the treatment or prevention of blood or bleeding disorders, namely, human albumin, coagulation factors and coagulation inhibitors, in particular factor VIII, factor IX, factor X, fibrinogen; pharmaceutical preparations for the treatment or prevention of blood or bleeding disorders, namely, immunoglobulin preparations, immunoglobulins and hyperimmunoglobulins; pharmaceutical preparations for the treatment or prevention of blood or bleeding disorders, namely, recombinant proteins, in particular coagulation factors and monoclonal antibodies; pharmaceutical preparations for haematology, immunology, neurology, intensive medicine, transplantation medicine, oncology for the prevention and treatment of immune system-related diseases and disorders, neurological diseases and disorders, cancer and infections; pharmaceutical preparations for preventing and treating viral diseases, for treating diseases of the immune system, for treating autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiallergic, hyposensitizing and detoxifying and toxin-neutralizing medicinesACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 15, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 14, 2026EX5GSOU EXTENSION 5 GRANTED
Aug 7, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 23, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 22, 2026EXT5SOU EXTENSION 5 FILED
Sep 15, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 4, 2025EX4GSOU EXTENSION 4 GRANTED
Sep 4, 2025EXT4SOU EXTENSION 4 FILED
Sep 4, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 5, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 4, 2025EX3GSOU EXTENSION 3 GRANTED
Apr 4, 2025EXT3SOU EXTENSION 3 FILED
Apr 4, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 7, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 7, 2024EX2GSOU EXTENSION 2 GRANTED
Oct 7, 2024EXT2SOU EXTENSION 2 FILED
Oct 7, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 25, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 25, 2024EX1GSOU EXTENSION 1 GRANTED
Aug 15, 2024TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION
Aug 15, 2024NREVNOTICE OF REVIVAL - E-MAILED
Aug 15, 2024PETGPETITION TO REVIVE-GRANTED
Aug 15, 2024PROATEAS PETITION TO REVIVE RECEIVED
Jul 12, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 27, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 24, 2024EXT1SOU EXTENSION 1 FILED
Oct 24, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 29, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 29, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 9, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 13, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 13, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 13, 2023CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 13, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 10, 2023DOCKASSIGNED TO EXAMINER
Jun 28, 2022MAFRAPPLICATION FILING RECEIPT MAILED
Jun 24, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 22, 2022DOCKASSIGNED TO EXAMINER
Jun 22, 2022TRPTREQUEST FOR TRANSFORMATION PROCESSED - TOTAL

Frequently asked questions

Related guidance